The COVID-19 pandemic has prompted pharmaceutical companies across the world to develop contingency plans to tackle potential disruptions.

GlobalData has conducted a survey to determine if companies across North America, Asia Pacific (APAC), Europe and Rest of World (ROW) have developed scenarios to respond to coronavirus-related disruptions.

An analysis of the survey responses has revealed that planning for COVID-19 related disruptions was highest in North America in Q3 at 91%, compared to 78% in Q1, as companies began to develop contingency plans.

Planning scenarios related to COVID-19 by region

In Europe, the percentage of companies that had developed planning scenarios increased from 63% in Q1 to 71% in Q3.

The survey, further, found that 56% of the respondents from APAC had planned for disruptions related to COVID-19 in Q1, which increased to 67% in Q3. For companies in ROW, however, the figure dropped from 70% in Q1 to 60% in Q3.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

The analysis is based on responses received from the Pharmaceutical Trade and Supply Chain Survey conducted between 07 July and 30 July 2020.